TABLE 1

Baseline clinical characteristics of patients

pSS (n = 17)HC(n = 16)P-value
Age, mean (s.d.)49.23 (14.37)44.38 (8.27)0.531
Female, n (%)16 (94.12)15 (93.75)0.965
Autoantibodies, n (%)
 ANA positive16 (94.12)
 Anti-SSA positive16 (94.12)
 Anti-SSB positive12 (70.59)
 Anti-Ro-52 positive16 (94.12)
pSS (n = 17)HC(n = 16)P-value
Age, mean (s.d.)49.23 (14.37)44.38 (8.27)0.531
Female, n (%)16 (94.12)15 (93.75)0.965
Autoantibodies, n (%)
 ANA positive16 (94.12)
 Anti-SSA positive16 (94.12)
 Anti-SSB positive12 (70.59)
 Anti-Ro-52 positive16 (94.12)

Data are expressed as n (%) or mean (s.d.). ANA: anti-nuclear antibodies; anti-SSA: anti-Ro/SSA antibodies; anti-SSB: anti- La/SSB antibodies; anti-Ro-52: anti-Ro-52 antibodies.

TABLE 1

Baseline clinical characteristics of patients

pSS (n = 17)HC(n = 16)P-value
Age, mean (s.d.)49.23 (14.37)44.38 (8.27)0.531
Female, n (%)16 (94.12)15 (93.75)0.965
Autoantibodies, n (%)
 ANA positive16 (94.12)
 Anti-SSA positive16 (94.12)
 Anti-SSB positive12 (70.59)
 Anti-Ro-52 positive16 (94.12)
pSS (n = 17)HC(n = 16)P-value
Age, mean (s.d.)49.23 (14.37)44.38 (8.27)0.531
Female, n (%)16 (94.12)15 (93.75)0.965
Autoantibodies, n (%)
 ANA positive16 (94.12)
 Anti-SSA positive16 (94.12)
 Anti-SSB positive12 (70.59)
 Anti-Ro-52 positive16 (94.12)

Data are expressed as n (%) or mean (s.d.). ANA: anti-nuclear antibodies; anti-SSA: anti-Ro/SSA antibodies; anti-SSB: anti- La/SSB antibodies; anti-Ro-52: anti-Ro-52 antibodies.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close